Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...

Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...

Levi Garraway, Roche’s chief medical officer and head of global product development, said: “The INAVO120 overall survival ...

Shares in Swiss pharma giant Roche were more than 1% higher on Tuesday afternoon, following the announcement of positive ...

The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.

The Phase III INAVO120 trial found that a combination of Itovebi (inavolisib) with Ibrance (palbociclib) and Faslodex (fulvestrant) significantly improved overall survival and progression-free ...

The FDA has given Roche its first regulatory approval for PI3K inhibitor Itovebi, clearing the drug as part of a triple therapy for certain types of locally advanced or metastatic breast cancer.

Genentech, a member of Roche (RHHBY), announced topline results from the overall survival analysis of the Phase III INAVO120 study ...

Sanjiv Patel, President and CEO of Relay Therapeutics, Inc. (NASDAQ:RLAY), recently executed a series of stock sales totaling $1.76 million. These transactions, conducted over three consecutive days, ...

Novartis won FDA approval for its PI3Kα inhibitor Piqray in 2019. Roche’s Itovebi joined the party late last year. Lilly’s attempt to follow its peers took a hit last year when it axed LOXO ...

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals, though skepticism remains.